Vaxxinity has announced that the Phase I clinical trial for its Parkinson’s vaccine (UB-312) met the primary objectives, achieving antibody response in early Parkinson’s disease (PD).
Vaxxinity CEO Mei Mei Hu attributes the company’s support for Phase II trials for UB-312 based on the data indicating that the antibody response from the vaccine crossed the blood-brain barrier, making the vaccine a “promising candidate” for Parkinson’s prevention or disease modification.
UB-312 is a synthetic peptide vaccine. It targets toxic forms of aggregated anti-alpha-synuclein (aSyn), which controls synaptic functions and regulates the release of neurotransmitters. Thus, aggregation of aSyn plays a key role in Parkinson’s development and progression.
A joint two-year project by Vaxxinity, Mayo Clinic, and the University of Texas is underway to assess target engagement assay and characterisation of UB-312 induced anti-aSyn antibodies. This project is funded by the Michael J Fox Foundation.
GlobalData has identified that the incomplete understanding of Parkinson’s aetiology and pathophysiology is a major challenge for drug development. However, the PD global market is expected to grow to $11.5bn in 2029.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
GlobalData is the parent company of Clinical Trials Arena.
Phase I data
The reported data is from the Part B of the randomised, placebo-controlled Phase I trial (NCT04075318), which enrolled patients with PD. The results from the Part A of the trial with healthy volunteers were published in 2022.
Thirteen patients completed dosing with UB-312 for 20 weeks. Twelve of these patients developed anti-aSyn antibodies that were also detectable beyond the blood-brain barrier in the cerebrospinal fluid (CSF).
Two patients had serious adverse events during the treatment and subsequent follow-up period (24 weeks). The adverse event profile was similar for the placebo and treatment groups.
The Phase I trial was conducted at an independent institute in the Netherlands, the Centre for Human Drug Research (CHDR).